Oyster Point Pharma Inc

$21.00 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Oyster Point Pharma Inc

Oyster Point Pharma, Inc. is a clinical stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its lead product candidate is OC-01 (varenicline), a selective nicotinic acetylcholine receptor (nAChR) agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). OC-01’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the TPP and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity, and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.

Stock Analysis

last close $21
1-mo return 2.3%
3-mo return 8.2%
avg daily vol. 79.22T
52-week high 36.9
52-week low 17.24
market cap. $481M
forward pe -
annual div. -
roe -43.5%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 87.6%

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist